Italian Lung Cancer Observational Study (LUCENT)

April 30, 2023 updated by: The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

LUCENT is an observational study focused on malignant pulmonary and tracheo-bronchial disease. It involves a large proportion of reference Italian thoracic surgery centers. The relevance of the study is related to the epidemiology of lung cancer in the world - also known as "Big Killer" - and the high mortality rates both in males and females.

The aim of his prospective study is to collect a large bulk of postoperative patients' outcome data and to produce up-to-date descriptive statistics of patients undergoing surgery for lung cancer. These results will be pivotal to compare the clinical results of all the relevant specialities involved in the care of lung cancer such as medical oncologists and radiation oncologists.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Observational

Enrollment (Anticipated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • L'Aquila, Italy, 67100
        • University of L'Aquila

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

PaTientsin with lung cancer and an indication for respective surgery

Description

Inclusion Criteria:

  • Patients with lung cancer
  • informed consent

Exclusion Criteria:

  • alcohol or drug abuse
  • age < 18
  • inability to express consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lung cancer surgery outcomes
Time Frame: 5 years
Benchmarking national outcome data of the treatment of lung cancer
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

Collaborators

Azienda Ospedaliero, Universitaria Pisana
Università degli Studi di Ferrara
Azienda Ospedaliera di Perugia
University of Milan
Monaldi Hospital
European Institute of Oncology
Università degli Studi dell'Aquila
AUSL Romagna Rimini
Azienda Policlinico Umberto I
S. Andrea Hospital
Azienda Ospedaliera di Bolzano
Azienda Socio Sanitaria Territoriale di Mantova

Investigators

  • Principal Investigator: Roberto Crisci, MD, University of Aquila
  • Principal Investigator: Luca Bertolaccini, MD, European Institute of Oncology
  • Principal Investigator: Alessandro Bertani, MD, IRCCS ISMETT -UPMC ITALY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2023

Primary Completion (Anticipated)

March 31, 2028

Study Completion (Anticipated)

March 31, 2028

Study Registration Dates

First Submitted

April 30, 2023

First Submitted That Met QC Criteria

April 30, 2023

First Posted (Actual)

May 10, 2023

Study Record Updates

Last Update Posted (Actual)

May 10, 2023

Last Update Submitted That Met QC Criteria

April 30, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRRB/04/23

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe